1
|
Boboescu IZ, Damay J, Chang JKW, Beigbeder JB, Duret X, Beauchemin S, Lalonde O, Lavoie JM. Ethanol production from residual lignocellulosic fibers generated through the steam treatment of whole sorghum biomass. Bioresour Technol 2019; 292:121975. [PMID: 31445238 DOI: 10.1016/j.biortech.2019.121975] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Revised: 08/06/2019] [Accepted: 08/07/2019] [Indexed: 06/10/2023]
Abstract
Cellulosic ethanol could play a major role in the upcoming circular-economy once the process complexity, low carbohydrate extraction yields and high costs are resolved. To this purpose, different steam-treatment severity factors were employed on whole sweet sorghum biomass, followed by the delignification and hydrolysis of resulted lignocellulose fibers. A modified ASTM International (American Society for Testing and Material) standard cellulose hydrolysis approach as well as a newly developed SACH (Sulfuric Acid Cellulose Hydrolysis) process were used, recovering up to 24.3 wt% of cellulosic carbohydrates. This amounted to a total extractable and constitutive carbohydrate recovery of 51.7 wt% (dry basis) when a mild steam-treatment of whole sorghum biomass and the SACH cellulose hydrolysis were employed. An ethanol potential of 6378 L/ha/year was determined, comparable to values obtained from biomass such as sugarcane in warmer climates, supporting thus the opportunity of implementing this novel approach on a wider scale.
Collapse
Affiliation(s)
- Iulian-Zoltan Boboescu
- Biomass Technology Laboratory (BTL), Department of Chemical Engineering and Biotechnological Engineering, University of Sherbrooke, QC, Canada
| | - Jérémie Damay
- Biomass Technology Laboratory (BTL), Department of Chemical Engineering and Biotechnological Engineering, University of Sherbrooke, QC, Canada
| | - James Kong Win Chang
- Biomass Technology Laboratory (BTL), Department of Chemical Engineering and Biotechnological Engineering, University of Sherbrooke, QC, Canada
| | - Jean-Baptiste Beigbeder
- Biomass Technology Laboratory (BTL), Department of Chemical Engineering and Biotechnological Engineering, University of Sherbrooke, QC, Canada
| | - Xavier Duret
- Biomass Technology Laboratory (BTL), Department of Chemical Engineering and Biotechnological Engineering, University of Sherbrooke, QC, Canada
| | - Sophie Beauchemin
- Biomass Technology Laboratory (BTL), Department of Chemical Engineering and Biotechnological Engineering, University of Sherbrooke, QC, Canada
| | | | - Jean-Michel Lavoie
- Biomass Technology Laboratory (BTL), Department of Chemical Engineering and Biotechnological Engineering, University of Sherbrooke, QC, Canada.
| |
Collapse
|
2
|
Beauchemin S, Clemente JS, Thibault Y, Langley S, Gregorich EG, Tisch B. Geochemical stability of acid-generating pyrrhotite tailings 4 to 5 years after addition of oxygen-consuming organic covers. Sci Total Environ 2018; 645:1643-1655. [PMID: 30248881 DOI: 10.1016/j.scitotenv.2018.07.261] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Revised: 07/11/2018] [Accepted: 07/18/2018] [Indexed: 06/08/2023]
Abstract
Oxygen-consuming organic covers can serve as a reactive barrier to minimize sulfide oxidation in acid-generating tailings but may lead to metal mobilization in surface oxidized layers. We evaluated changes in the bio-geochemical stability of acid-generating, Cu-Ni pyrrhotite tailings 4 to 5 years after addition of a 50 cm-thick or a 1 m-thick biosolid cover planted with energy crops. The original tailings (pH 2.5) were oxidized in the first 10 to 40 cm, and goethite was the dominant sink for Cu and Ni, the main metal contaminants in these tailings. Both covers increased pH, nutrient availability, microbial activity and diversity in the oxidized tailings, and led to a reduction of water-soluble Cu, Ni, Fe and Al after 4 to 5 years of application. Changes in pH, humidity, organic C content, and redox conditions resulted in partial dissolution of jarosite and gypsum below the cover but goethite apparently remained stable. Under both covers, total Ni decreased in the oxidized layer, indicating remobilization, but Cu was retained. Significant accumulation of Cu as Cu sulfide at the oxidized/unoxidized tailings interface was detected only under the 1 m-thick cover, suggesting that the thinner cover may not sufficiently decrease the oxidizing conditions to mitigate acid mine drainage. Migration of nitrate and P down to the unoxidized tailings was observed under both covers and raises the concern of continued sulfide oxidation in unoxidized tailings. Although the implementation of thinner covers is economically more sustainable than thick covers, our results indicate that further research is required to establish their long-term suitability and performance to prevent acid mine drainage.
Collapse
Affiliation(s)
- S Beauchemin
- Natural Resources Canada, CanmetMINING, 555 Booth, Ottawa, Ontario K1A 0G1, Canada.
| | - J S Clemente
- Natural Resources Canada, CanmetMINING, 555 Booth, Ottawa, Ontario K1A 0G1, Canada
| | - Y Thibault
- Natural Resources Canada, CanmetMINING, 555 Booth, Ottawa, Ontario K1A 0G1, Canada
| | - S Langley
- Natural Resources Canada, CanmetMINING, 555 Booth, Ottawa, Ontario K1A 0G1, Canada
| | - E G Gregorich
- Agriculture and Agri-Food Canada, 960 Carling, Ottawa, Ontario K1A 0C6, Canada
| | - B Tisch
- Natural Resources Canada, CanmetMINING, 555 Booth, Ottawa, Ontario K1A 0G1, Canada
| |
Collapse
|
3
|
Bella Ndong D, Blais V, Holleran BJ, Proteau-Gagné A, Cantin-Savoie I, Robert W, Nadon JF, Beauchemin S, Leduc R, Piñeyro G, Guérin B, Gendron L, Dory YL. Exploration of the fifth position of leu-enkephalin and its role in binding and activating delta (DOP) and mu (MOP) opioid receptors. Pept Sci (Hoboken) 2018. [DOI: 10.1002/pep2.24070] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Dominique Bella Ndong
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Biochimie, Faculté de Médecine et des Sciences de la Santé; Université de Sherbrooke; Sherbrooke Québec Canada
| | - Véronique Blais
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé; Université de Sherbrooke; Sherbrooke Québec Canada
| | - Brian J. Holleran
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé; Université de Sherbrooke; Sherbrooke Québec Canada
| | - Arnaud Proteau-Gagné
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Chimie, Facult des Sciences; Université de Sherbrooke; Sherbrooke Québec Canada
| | - Isabelle Cantin-Savoie
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Chimie, Facult des Sciences; Université de Sherbrooke; Sherbrooke Québec Canada
| | - William Robert
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé; Université de Sherbrooke; Sherbrooke Québec Canada
| | - Jean-François Nadon
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Chimie, Facult des Sciences; Université de Sherbrooke; Sherbrooke Québec Canada
| | - Sophie Beauchemin
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Chimie, Facult des Sciences; Université de Sherbrooke; Sherbrooke Québec Canada
| | - Richard Leduc
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé; Université de Sherbrooke; Sherbrooke Québec Canada
- Centre de recherche du CHU de Sherbrooke; Sherbrooke Québec Canada
| | - Graciela Piñeyro
- Département de Psychiatrie, Centre de Recherche du CHU Ste-Justine; Université de Montréal; Montreal Québec Canada
| | - Brigitte Guérin
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Centre de recherche du CHU de Sherbrooke; Sherbrooke Québec Canada
- Département de Médecine Nucléaire et de Radiobiologie, Faculté de Médecine et des Sciences de la Santé; Université de Sherbrooke; Sherbrooke Québec Canada
| | - Louis Gendron
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé; Université de Sherbrooke; Sherbrooke Québec Canada
- Centre de recherche du CHU de Sherbrooke; Sherbrooke Québec Canada
| | - Yves L. Dory
- Institut de Pharmacologie, Université de Sherbrooke, 3001 12 av. Nord; Sherbrooke Québec J1H 5N4 Canada
- Département de Chimie, Facult des Sciences; Université de Sherbrooke; Sherbrooke Québec Canada
- Centre de recherche du CHU de Sherbrooke; Sherbrooke Québec Canada
| |
Collapse
|
4
|
Naud J, Harding J, Lamarche C, Beauchemin S, Leblond FA, Pichette V. Effects of Chronic Renal Failure on Brain Cytochrome P450 in Rats. Drug Metab Dispos 2016; 44:1174-9. [DOI: 10.1124/dmd.116.070052] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Accepted: 05/18/2016] [Indexed: 11/22/2022] Open
|
5
|
Kwiatkowska A, Couture F, Levesque C, Ly K, Beauchemin S, Desjardins R, Neugebauer W, Dory YL, Day R. Inside Cover: Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors (ChemMedChem 3/2016). ChemMedChem 2016. [DOI: 10.1002/cmdc.201600031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Anna Kwiatkowska
- Département de Chirurgie/Urologie; Faculté de Médecine et Sciences de la Santé; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Sherbrooke Québec J1H 5N4 Canada
| | - Frédéric Couture
- Département de Chirurgie/Urologie; Faculté de Médecine et Sciences de la Santé; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Sherbrooke Québec J1H 5N4 Canada
| | - Christine Levesque
- Département de Chirurgie/Urologie; Faculté de Médecine et Sciences de la Santé; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Sherbrooke Québec J1H 5N4 Canada
| | - Kévin Ly
- Département de Chirurgie/Urologie; Faculté de Médecine et Sciences de la Santé; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Sherbrooke Québec J1H 5N4 Canada
| | - Sophie Beauchemin
- Département de chimie; Faculté des Sciences; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Québec J1H 5N4 Canada
| | - Roxane Desjardins
- Département de Chirurgie/Urologie; Faculté de Médecine et Sciences de la Santé; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Sherbrooke Québec J1H 5N4 Canada
| | - Witold Neugebauer
- Département de Chirurgie/Urologie; Faculté de Médecine et Sciences de la Santé; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Sherbrooke Québec J1H 5N4 Canada
| | - Yves L. Dory
- Département de chimie; Faculté des Sciences; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Québec J1H 5N4 Canada
| | - Robert Day
- Département de Chirurgie/Urologie; Faculté de Médecine et Sciences de la Santé; Institut de pharmacologie de Sherbrooke; Université de Sherbrooke, 3001; 12e Ave. Nord Sherbrooke Sherbrooke Québec J1H 5N4 Canada
| |
Collapse
|
6
|
Kwiatkowska A, Couture F, Levesque C, Ly K, Beauchemin S, Desjardins R, Neugebauer W, Dory YL, Day R. Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors. ChemMedChem 2016; 11:289-301. [PMID: 26751825 DOI: 10.1002/cmdc.201500532] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Indexed: 12/12/2022]
Abstract
PACE4 plays important roles in prostate cancer cell proliferation. The inhibition of this enzyme has been shown to slow prostate cancer progression and is emerging as a promising therapeutic strategy. In previous work, we developed a highly potent and selective PACE4 inhibitor, the multi-Leu (ML) peptide, an octapeptide with the sequence Ac-LLLLRVKR-NH2 . Here, with the objective of developing a useful compound for in vivo administration, we investigate the effect of N-terminal modifications. The inhibitory activity, toxicity, stability, and cell penetration properties of the resulting analogues were studied and compared to the unmodified inhibitor. Our results show that the incorporation of a polyethylene glycol (PEG) moiety leads to a loss of antiproliferative activity, whereas the attachment of a lipid chain preserves or improves it. However, the lipidated peptides are significantly more toxic when compared with their unmodified counterparts. Therefore, the best results were achieved not by the N-terminal extension but by the protection of both ends with the d-Leu residue and 4-amidinobenzylamide, which yielded the most stable inhibitor, with an excellent activity and toxicity profile.
Collapse
Affiliation(s)
- Anna Kwiatkowska
- Département de Chirurgie/Urologie, Faculté de Médecine et Sciences de la Santé, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada
| | - Frédéric Couture
- Département de Chirurgie/Urologie, Faculté de Médecine et Sciences de la Santé, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada
| | - Christine Levesque
- Département de Chirurgie/Urologie, Faculté de Médecine et Sciences de la Santé, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada
| | - Kévin Ly
- Département de Chirurgie/Urologie, Faculté de Médecine et Sciences de la Santé, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada
| | - Sophie Beauchemin
- Département de chimie, Faculté des Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord, Sherbrooke, Québec, J1H 5N4, Canada
| | - Roxane Desjardins
- Département de Chirurgie/Urologie, Faculté de Médecine et Sciences de la Santé, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada
| | - Witold Neugebauer
- Département de Chirurgie/Urologie, Faculté de Médecine et Sciences de la Santé, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada
| | - Yves L Dory
- Département de chimie, Faculté des Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord, Sherbrooke, Québec, J1H 5N4, Canada.
| | - Robert Day
- Département de Chirurgie/Urologie, Faculté de Médecine et Sciences de la Santé, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Ave. Nord Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada.
| |
Collapse
|
7
|
Gagnon H, Beauchemin S, Kwiatkowska A, Couture F, D'Anjou F, Levesque C, Dufour F, Desbiens AR, Vaillancourt R, Bernard S, Desjardins R, Malouin F, Dory YL, Day R. Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J Med Chem 2013; 57:29-41. [PMID: 24359257 DOI: 10.1021/jm400633d] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Proprotein convertases (PCs) are crucial in the processing and entry of viral or bacterial protein precursors and confer increased infectivity of pathogens bearing a PC activation site, which results in increased symptom severity and lethality. Previously, we developed a nanomolar peptide inhibitor of PCs to prevent PC activation of infectious agents. Herein, we describe a peptidomimetic approach that increases the stability of this inhibitor for use in vivo to prevent systemic infections and cellular damage, such as that caused by influenza H5N1 and Shiga toxin. The addition of azaβ(3)-amino acids to both termini of the peptide successfully prevented influenza hemagglutinin 5 fusogenicity and Shiga toxin Vero toxicity in cell-based assays. The results from a cell-based model using stable shRNA-induced proprotein convertase knockdown indicate that only furin is the major proprotein convertase required for HA5 cleavage.
Collapse
Affiliation(s)
- Hugo Gagnon
- Institut de Pharmacologie de Sherbrooke (IPS) and Département de Chirurgie/Urologie, Faculté de Médecine et des Sciences de la Santé (FMSS), Université de Sherbrooke , 3001, 12e Avenue Nord, Sherbrooke, Québec J1H 5N4, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Kwiatkowska A, Couture F, Levesque C, Ly K, Desjardins R, Beauchemin S, Prahl A, Lammek B, Neugebauer W, Dory YL, Day R. Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem 2013; 57:98-109. [PMID: 24350995 DOI: 10.1021/jm401457n] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
PACE4 plays an important role in the progression of prostate cancer and is an attractive target for the development of novel inhibitor-based tumor therapies. We previously reported the design and synthesis of a novel, potent, and relatively selective PACE4 inhibitor known as a Multi-Leu (ML) peptide. In the present work, we examined the ML peptide through detailed structure-activity relationship studies. A variety of ML-peptide analogues modified at the P8-P5 positions with leucine isomers (Nle, DLeu, and DNle) or substituted at the P1 position with arginine mimetics were tested for their inhibitory activity, specificity, stability, and antiproliferative effect. By incorporating d isomers at the P8 position or a decarboxylated arginine mimetic, we obtained analogues with an improved stability profile and excellent antiproliferative properties. The DLeu or DNle residue also has improved specificity toward PACE4, whereas specificity was reduced for a peptide modified with the arginine mimetic, such as 4-amidinobenzylamide.
Collapse
Affiliation(s)
- Anna Kwiatkowska
- Institut de Pharmacologie de Sherbrooke, Department of Surgery/Urology Division, Université de Sherbrooke , 3001 12th Avenue North, Sherbrooke, Québec, J1H 5N4, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Bossy A, Grosbois C, Hendershot W, Beauchemin S, Crouzet C, Bril H. Contributions of natural arsenic sources to surface waters on a high grade arsenic-geochemical anomaly (French Massif Central). Sci Total Environ 2012; 432:257-268. [PMID: 22750171 DOI: 10.1016/j.scitotenv.2012.05.090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2012] [Revised: 05/24/2012] [Accepted: 05/28/2012] [Indexed: 06/01/2023]
Abstract
The subwatershed studied drains a non-exploited area of the St-Yrieix-la-Perche gold mining district (French Massif Central) and it is located on an arsenic (As) geochemical anomaly. In this context, it is important to know the geochemical processes involved in the transfer of As from solid environmental compartments to the aquatic system. The stream showed a temporal variation of dissolved As (As(d)) content from 69.4 μg.L(-1) in the low flow period to 7.5 μg.L(-1) in the high flow period. Upstream, ground- and wetland waters had As(d) concentrations up to 215 and 169 μg.L(-1), respectively. The main representative As sources were determined at the subwatershed scale with in-situ monitoring of major and trace element contents in different waters and single extraction experiments. The As sources to stream water could be regrouped into two components: (i) one As-rich group (mainly in the low flow period) with groundwater, gallery exploration outlet waters and wetland waters, and (ii) one As-poor group (mainly in the high flow period) with rainwaters and soil solutions. In the soil profile, As(d) showed a significant decrease from 52.4 μg.L(-1) in the 0-5 cm superficial soil horizon to 14.4 μg.L(-1) in the 135-165 cm deep soil horizon. This decrease may be related to pedogenic processes and suggests an evolution of As-bearing phase stability through the soil profile. Quantification of As(d) fluxes at the subwatershed scale showed that groundwater was the major input (>80%) of As(d) to surface water. Moreover, natural weathering of the As-rich solid phases showed an impact on the As release, mainly from superficial soil horizons with runoff contributing about 5% to As input in surface water.
Collapse
Affiliation(s)
- A Bossy
- Université de Limoges, GRESE EA 4330, F.S.T., 123 av. Albert Thomas, 87060 Limoges Cedex, France
| | | | | | | | | | | |
Collapse
|
10
|
Hoveyda HR, Marsault E, Gagnon R, Mathieu AP, Vézina M, Landry A, Wang Z, Benakli K, Beaubien S, Saint-Louis C, Brassard M, Pinault JF, Ouellet L, Bhat S, Ramaseshan M, Peng X, Foucher L, Beauchemin S, Bhérer P, Veber DF, Peterson ML, Fraser GL. Optimization of the Potency and Pharmacokinetic Properties of a Macrocyclic Ghrelin Receptor Agonist (Part I): Development of Ulimorelin (TZP-101) from Hit to Clinic. J Med Chem 2011; 54:8305-20. [DOI: 10.1021/jm2007062] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Hamid R. Hoveyda
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Eric Marsault
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - René Gagnon
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Axel P. Mathieu
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Martin Vézina
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Annick Landry
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Zhigang Wang
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Kamel Benakli
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Sylvie Beaubien
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Carl Saint-Louis
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Martin Brassard
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | | | - Luc Ouellet
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Shridhar Bhat
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Mahesh Ramaseshan
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Xiaowen Peng
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Laurence Foucher
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Sophie Beauchemin
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Patrick Bhérer
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Daniel F. Veber
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Mark L. Peterson
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| | - Graeme L. Fraser
- Tranzyme Pharma Inc., 3001,
12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
| |
Collapse
|
11
|
Marsault E, Hoveyda HR, Peterson ML, Gagnon R, Vézina M, Pinault J, Landry A, Saint-Louis C, Ouellet LG, Beauchemin S, Benakli K, Beaubien S, Brassard M, Wang Z, Champagne M, Galaud F, Fortin N, Fortin D, Plourde V, Ramaseshan M, Bhat S, Bilodeau F, Lonergan D, Lan R, Li S, Berthiaume G, Foucher L, Peng X, Dory Y, Deslongchamps P. High Throughput Solid Phase Parallel Synthesis of Macrocyclic Peptidomimetics. Advances in Experimental Medicine and Biology 2009; 611:15-6. [DOI: 10.1007/978-0-387-73657-0_7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
12
|
Marsault E, Hoveyda HR, Gagnon R, Peterson ML, Vézina M, Saint-Louis C, Landry A, Pinault JF, Ouellet L, Beauchemin S, Beaubien S, Mathieu A, Benakli K, Wang Z, Brassard M, Lonergan D, Bilodeau F, Ramaseshan M, Fortin N, Lan R, Li S, Galaud F, Plourde V, Champagne M, Doucet A, Bhérer P, Gauthier M, Olsen G, Villeneuve G, Bhat S, Foucher L, Fortin D, Peng X, Bernard S, Drouin A, Déziel R, Berthiaume G, Dory YL, Fraser GL, Deslongchamps P. Efficient parallel synthesis of macrocyclic peptidomimetics. Bioorg Med Chem Lett 2008; 18:4731-5. [PMID: 18640834 DOI: 10.1016/j.bmcl.2008.06.085] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2008] [Revised: 06/25/2008] [Accepted: 06/25/2008] [Indexed: 10/21/2022]
Abstract
A new method for solid phase parallel synthesis of chemically and conformationally diverse macrocyclic peptidomimetics is reported. A key feature of the method is access to broad chemical and conformational diversity. Synthesis and mechanistic studies on the macrocyclization step are reported.
Collapse
Affiliation(s)
- Eric Marsault
- Tranzyme Pharma Inc. 3001, 12e av. Nord, Sherbrooke, Que., Canada J1H5N4.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Marsault E, Hoveyda HR, Peterson ML, Saint-Louis C, Landry A, Vézina M, Ouellet L, Wang Z, Ramaseshan M, Beaubien S, Benakli K, Beauchemin S, Déziel R, Peeters T, Fraser GL. Discovery of a New Class of Macrocyclic Antagonists to the Human Motilin Receptor. J Med Chem 2006; 49:7190-7. [PMID: 17125271 DOI: 10.1021/jm0606600] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A novel class of macrocyclic peptidomimetics was identified and optimized as potent antagonists to the human motilin receptor (hMOT-R). Well-defined structure-activity relationships allowed for rapid optimization of potency that eventually led to high affinity antagonists to hMOT-R. Potency and antagonist functional activity were confirmed both in functional and cell-based assays, as well as on isolated rabbit intestinal smooth muscle strips. Rapid access to this novel class of macrocyclic target structures was made possible through two efficient and complementary solid-phase parallel synthetic approaches, both of which are reported herein.
Collapse
Affiliation(s)
- Eric Marsault
- Tranzyme Pharma Inc., 3001, 12e Avenue Nord, Sherbrooke, PQ, Canada, J1H 5N4.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Hesterberg D, Zhou W, Hutchison KJ, Beauchemin S, Sayers DE. XAFS study of adsorbed and mineral forms of phosphate. J Synchrotron Radiat 1999; 6:636-638. [PMID: 15263406 DOI: 10.1107/s0909049599000370] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/1998] [Accepted: 01/06/1999] [Indexed: 05/24/2023]
|